The ferroxidase HEPHaestin in Lung cancer: Pathological Significance and Prognostic Value

Paola Zacchi¹, Beatrice Belmonte², Alessandro Mangogna³, Gaia Morello², Letizia Scola⁴, Anna Martorana², Violetta Borelli^{1*}

¹Department of Life Sciences, University of Trieste, Trieste, Italy

²Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy

³Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy

⁴Clinical Pathology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo, 90100 Palermo, Italy.

***Corresponding author:**

Borelli Violetta

borelliv@units.it

Keywords: Hephaestin, iron metabolism, lung cancer, tumor microenvironment, stromal cells, immune infiltrate

Abstract

Iron is a fundamental nutrient utilized by living cells to support several key cellular processes. Despite its paramount role to sustain cell survival, excess of labile iron availability can inflict severe cell damage via reactive oxygen species generation which, in turn, can promote neoplastic transformation. The lung is particularly sensitive to iron-induced oxidative stress, given the high oxygen tensions herein present. Moreover, cigarette smoke as well as air pollution particulate can function as vehicles of iron supply, leading to an iron dysregulation condition shown to be crucial in the pathogenesis of several respiratory diseases including lung cancer. Hephaestin (HEPH) belongs to a group of exocytosomal ferroxidases emerged to contribute to cellular iron homeostasis by favouring its export. Although HEPH can affect the concentration of intracellular iron labile pool, its expression in lung cancer and its influence on prognosis have not been investigated.

In this study we explored the expression pattern and prognostic value of HEPH in the most prevalent histotypes of lung cancers including lung adenocarcinoma and lung squamous cell carcinoma across in silico analyses using UALCAN, Gepia and Kaplan-Meier plotter bioinformatics. We took advantage of TIMER to assess the correlation between HEPH and tumour infiltrating immune and non-immune cells. Then we performed immunohistochemical analysis to dissect the presence of HEPH either in “healthy” and tumor lung tissues. Overall, our data suggest a positive correlation between higher level of HEPH expression with a favorable prognosis in both cancer histotypes.

Introduction preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Lung cancer represents the most frequent malignant neoplasm in most countries and the leading cause of death worldwide in both sexes (1). The incidence of lung cancer is low in people aged below 40 years but it dramatically increases up to age 60-65 years in most populations. The most common subtype of lung cancer is non-small cell lung cancer (NSCLC; 85%), classified into lung adenocarcinoma (LUAD), the most prevalent form, followed by lung squamous cell carcinoma (LUSC) and large cell carcinoma (2). Smoking status is certainly the most important causative link in lung cancer development even though air pollution represents another paramount source of risk factor. Airborne Particulate matter (PM), in particular the small size components (PM₁₀, PM_{2.5} and ultrafine particles-UFP), which include combustion products, soot, exhaust emission from vehicles and industrial processes, have attracted attention mainly for two reasons: firstly, these particles, due to their small size, remain suspended in the air for quite a long time, thus increasing the chance of being inhaled; secondly, these particles are vehicles of chemical compounds, in particular transition metals, being iron present in significant concentration (3). Iron is also found in cigarette smoke, the strongest causative link to pulmonary pathology.

Iron toxicity relies on its high redox cycling reactivity which can drive the production of free radical species (ROS) known to promote many aspects of tumour development and progression (4). The lung is extremely sensitive to metal-induced oxidative stress due to its unique role for massive oxygen transfer into the bloodstream (5). Therefore, as a protective strategy to prevent ROS generation, lung epithelial cells have evolved a tight control on iron import, storage and export aimed at keeping its absolute concentration low, while sustaining the metabolic demand (6 REF Ghio 2009). Efficient iron uptake and intracellular sequestration can limit its toxicity but long-term storage can increase the probability of its possible mobilization, resulting in oxidative cell damage. Iron export mechanisms are therefore necessary to prevent its excessive intracellular accumulation, as it may occur upon exogenous iron supply via airborne pollutants inhalation. The only known non-heme iron export pathway relies on the activity of the transmembrane ferrous iron transporter ferroportin 1 (FPN1) also known as solute carrier family 40 member 1 (SLC40A1) (7) in conjunction with the large membrane-anchored copper-dependent ferroxidase (FOX) Hephaestin (HEPH), required to oxidized iron to its ferric form (8). In enterocytes FPN1 allows the translocation of iron across the basolateral membrane and its release into the bloodstream (9). In lung FPN1 is, instead, mainly expressed in the apical membrane of the airway epithelium (10) where it is supposed to promote iron release into the airways or the lumen of the alveoli to meet the need of detoxification. This egress pathway has been shown to be compromised in diverse types of cancers (11). In particular FPN1 mRNA expression levels appeared significantly down-regulated in lung tumour as compared to matched healthy tissue, a condition that is expected to guarantee an increase in the intracellular labile iron pool necessary for

all metabolic processes involved in cell proliferation (12). The role played by HEPH in iron metabolism in lung is still poorly characterized as well as its possible contribution to lung carcinogenesis and growth. We recently identified a single-nucleotide polymorphism within HEPH gene, leading to a missense variation of this multicopper ferroxidase, which results protective against asbestos-dependent malignant pleural mesothelioma and lung carcinoma (13, 14). Moreover, in breast cancer HEPH expression has been shown to be down-regulated by the histone methyltransferase G9a, leading to changes in iron homeostasis that burst cancer growth (15).

In the current study, we examined the expression and prognostic value of HEPH expression in LUAD and LUSC patients in databases such as UALCAN, GEPIA and Kaplan-Meier plotter. Moreover, we investigated the correlation of HEPH expression with tumour-infiltrating immune and non-immune cells characterizing the tumour microenvironment via Tumour Immune Estimation Resource (TIMER). Finally, we evaluated the distribution of endogenous HEPH in lung cancer tissues. These data altogether further support the key role played by iron dysregulation in the carcinogenic mechanism of lung malignancies

Materials and Methods

Gene expression and Survival analysis

Our analysis focused on the prognostic effect of *HEPH* gene in lung adenocarcinoma (LUAD) and in lung squamous cell carcinoma (LUSC). The expression level of the gene in different carcinomas was analyzed using UALCAN (<http://ualcan.path.uab.edu>) and GEPIA (<http://gepia.cancer-pku.cn>). Those tools estimate the effect of gene expression level on the patient survival in addition to be a web resource for analyzing cancer transcriptome data (16, 17). We compared the differences in mRNA level between cancers and normal tissue, using genomics data from “The Cancer Genome Atlas” (TCGA lung). The prognostic significance of *HEPH* mRNA expression and survival in LUAD and LUSC were analyzed by Kaplan Meier plotter (<https://kmplot.com/analysis>). Kaplan Meier plotter use genomics data from Gene Expression Omnibus, and European Genome-phenome Archive to generate survival probability plots and to perform survival analysis (2, 3). The same analysis was done for other genes (*ACTA2*, *FAP*, *PDGFRA*, *PDGFRB*, *PECAMI*, *vWF*). The hazard ratio with 95% confidence intervals and log-rank *p*-value were also computed. .

Protein Expression Analysis

The expression *HEPH* proteins between cancer and normal tissue were analyzed using UALCAN, which provided protein expression analysis option using data from Clinical Proteomic Tumor Analysis Consortium (CPTAC) Confirmatory/Discovery dataset (4). Unfortunately, at the time of writing, UALCAN tool provided data only for LUAD histotype.

TIMER Database Analysis

TIMER is a comprehensive resource for systematic analysis of immune infiltrates across diverse cancer types (www.cistrome.shinyapps.io/timer/) (18). TIMER applies a statistical method to infer the abundance of tumor-infiltrating immune cells (TIICs) from gene expression profiles using data from the TCGA dataset (19). We analyzed *HEPH* expression in lung cancers and the correlation between its expression with the abundance of immune infiltrates, including B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, cancer associated fibroblasts and endothelial cells via gene modules. These gene markers are referenced in prior studies (7, 8). Gene expression levels against tumor purity are also displayed (20, 21). The correlation module generated the expression scatter plots between several genes and defined genes of TIICs in chosen carcinomas, together with the Spearman’s correlation and the estimated statistical significance. Several genes were used for the x-

axis, and related marker genes are represented on the y-axis as genes of THICs. The gene expression level was displayed with log2 RSEM.

Statistical Analysis

Survival curves were generated by the Kaplan Meier plotter (22). All results are displayed with *p*-values from a log-rank test. *p*-values < 0.05 were considered significant. In TIMER, the correlation of gene expression was evaluated by Spearman's correlation and statistical significance, and the strength of the correlation was determined using the following guide for the absolute value: 0.00 - 0.19 "very weak," 0.20 - 0.39 "weak," 0.40 - 0.59 "moderate," 0.60 - 0.79 "strong," 0.80 - 1.0 "very strong".

Immunohistochemistry analysis on tumour tissues

All tissue samples of lung adenocarcinoma and lung squamous cell carcinoma enrolled for this study were collected according to the Helsinki Declaration and the study was approved by the University of Palermo Ethical Review Board (approval number 09/2018). Surgical normal tissue samples of lung and the malignant counterpart were selected for immunohistochemical analysis for HEPH expression. Invasive malignant neoplasia specimens included the two more represented histotypes including LUAD and LUCS. The study was approved by the Institutional review board of the University of Palermo (09/2018). A specific informed consent was not required at the time of tissue sample collection for the immunohistochemical analysis of archival tissue sections since the patients were not identified and genetic analysis was not carried out.

Immunohistochemistry was carried out on FFPE human tissue sections. Briefly, sections 4 micron-thick were cut from paraffin blocks, dried, de-waxed and rehydrated. The antigen unmasking technique was performed using Target Retrieval Solutions, pH=9 EDTA-based buffer in thermostatic bath at 98°C for 30 minutes. After the sections were brought at room temperature, the neutralization of the endogenous peroxidase with 3% H₂O₂ and protein blocking by a specific protein block were performed. For HEPH immunostaining, sections were probed with mouse monoclonal anti-human HEPH (Dilution 1:100, pH 6, Clone sc-365365 Santa Cruz Biotechnology) overnight at 4°C. Antibody-Antigen recognition was detected using Novolink Polymer Detection Systems (Novocastra Leica Biosystems, Newcastle) and employing the high sensitivity AEC (3-Amino9-Ethylcarbazole) as chromogen. Slides were counterstained with Harris Haematoxylin (Novocastra, Ltd).

All the sections were analyzed under Zeiss Axio Scope A1 optical microscope (Zeiss, Germany) and microphotographs were collected using an Axiocam 503 Color digital camera with the ZEN2 imaging software (Zeiss Germany).

RESULTS

The mRNA Expression Levels of HEPH in Different Types of Human Cancers

The ferroxidase HEPH has recently emerged to play a role in breast tumour cell growth; in particular its decreased expression has been significantly correlated with a poor survival in affected patients (15). In order to expand the analysis to other cancer types we examined HEPH expression using UALCAN that analyse TCGA RNA-sequencing and patients' clinical data from 33 different cancer types, including several metastatic tumors (22). This analysis unveiled that a significant down-regulation of the HEPH mRNA expression levels is found in several other malignancies such as BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), COAD (colon adenocarcinoma), KICH (kidney chromophobe), KIRP (kidney renal clear cell carcinoma), LIHC (liver hepatocellular carcinoma), LUAD (lung adenocarcinoma), LUSC (lung squamous adenocarcinoma), PRAD (prostate adenocarcinoma), READ (rectum adenocarcinoma), and UCEC (uterine corpus endometrial carcinoma) compared to the corresponding normal tissues (Fig. 1A).

Given our interest in better understanding the role iron's dysregulation may exert in lung cancer development and prognosis, we evaluated HEPH mRNA expression levels in the most prevalent histological types LUAD and LUSC, as compared to normal tissue, utilizing the GEPIA database. Consistently with the previous analysis, a significant decrease in HEPH mRNA expression was found in LUAD and LUSC, as compared to healthy controls (Fig. 1B) and this reduction was confirmed at the protein level only for LUAD histotype, based on UALCAN dataset (Fig. 1C), since corresponding proteomic data for LUSC are still not available.

To investigate the correlation between HEPH expression and patients' outcome we took advantage of the Kaplan-Meier overall survival curves to establish and compare the survival differences between patients with high and low expression of the ferroxidase (grouped according "Auto select best cutoff") (Fig. 1D). In both LUAD and LUSC datasets, the high expression group had a significantly longer overall survival than the low expression group, thus indicating that higher HEPH expression correlates with a better prognosis.

HEPH expression is correlated with immune and non-immune infiltration

It is well established that cancer cells are characterized by an iron-seeking phenotype, which is fundamental to support the enhanced metabolic demand characteristic of actively proliferating cells (23). This increased request of iron supply is achieved not only upon up-regulating iron import pathways while down-regulating storage and export routes but also by altering how other cell types of the tumor microenvironment, including immune cells, endothelial cells, pericytes and fibroblasts, metabolize iron. We therefore assessed the correlations of HEPH expression with immune and non-immune infiltration levels using TIMER web resource (22). In particular, we assessed, as immune infiltrate, B cells, CD4+ T cells, CD8+ T cells, macrophages and dendritic cells while cancer associated fibroblasts and endothelial cells were analysed as infiltrating non-immune cell types. The results showed that HEPH expression had a significant negative correlation with tumour purity, the parameter identifying the proportion of cancer cells present in the tumour tissue, in both type of lung cancers (Figure 2). In addition, HEPH expression demonstrated a very weak correlation with all infiltrating immune elements tested (Table 1), while a strong positive correlation was found only with cancer associated fibroblasts (CAFs) and endothelial cells (ECs) (Figure 2).

CAFs are the most abundant cells in solid cancer. They can derived from several sources including activation of resident fibroblasts (24), epithelial-mesenchymal transition of epithelial cells (25), endothelial-mesenchymal transition of resident endothelial cells (26). Compared to normal fibroblasts they are characterized by enhanced proliferative and migratory features, and they are also more metabolically active. Tumour endothelial cells refers to the cells lining the tumour-associated blood vessels that provide nutrition and oxygen to the tumour, contributing to its growth and development. They also constitute one of the main sources of cancer-associated fibroblasts (CAFs).

To further characterized the relationship between HEPH and these infiltrating cells in lung malignancies we explore the correlation between HEPH and a list of marker sets known to be widely used to identified CAFs and ECs, using the TIMER Gene Correlation module. In particular we used α -SMA (ACTA2, marker also for vascular muscular cells and pericytes), fibroblasts activation protein (FAP, also expressed in a subset of CD45+ immune cells), platelet-derived growth factor receptor- α/β (PDGFRA/B) as biological markers for CAFs (Figure 3A); PECAM1 (CD31) and von Willebrand Factor (vWF) as markers for the endothelial cells (Figure 3B). After the correlation adjustment by tumour purity, HEPH expression level was significantly correlated with all marker sets tested (Figure 3).

Interestingly we also found that the mRNA expression level of all these marker genes, with the only exception of FAP, were significantly down-regulated in both lung malignancies as compared with paired normal tissues, based on GEPIA datasets (Figure 4A). Moreover, Kaplan Meier analysis

indicated that high expression of ACTA2 and PDGFRA as well as PECAM1 and vWF were associated with better overall survival, as it is for HEPH expression (Figure 4B).

Distribution of HEPH in clinical LUAD and LUSC specimens

Based on the results obtained upon TIMER database analysis we aimed at better understanding the distribution of the HEPH in a series of specimens of LUAD and LUSC upon ferroxidase immunohistochemical labeling. As shown in Figure 5 panel A and B, the ferroxidase staining was quite intense on endothelial cells surrounding the vasculature in peri-tumour tissues, being endothelial cells and possibly pericytes immunoreactive for HEPH primary antibody. HEPH was also associated to macrophages, as identified by their spherical appearance and by the presence of a reniform nucleus, and neutrophils based on their small round shape and on a clearly identifiable multi-lobed nucleus (Figure 5B, see arrows).

In cancer tissues HEPH distribution appeared quite different in the two malignancies analyzed. In particular, in LUAD specimens we noticed that tumoral cells were totally lacking HEPH expression while the very few cells HEPH positive infiltrating the cancerous tissue were characterized by either a neutrophil-like or a spindle-like fibroblast morphology (Figure 6, panels B and D). There were also some macrophages immune-labeled, identified based on their morphological features. In LUSC, instead, we observed that about 30% of cancer cells, identified for their characteristic large polygonal shape, were positive, to variable extent, for HEPH labeling (Figure 7, panel B). Moreover, the tumour mass was massively infiltrated by HEPH-expressing cellular elements of neutrophil-like morphology and possibly also some monocyte/macrophages (Figure 7, panels A and C). There were also a consistent amount of HEPH positive mesenchymal cells exhibiting spindle-shaped morphology and recognized as fibroblastic stromal component (Figure 7, panels D).

These immune-labeling experiments, in agreement with the bioinformatics analysis, confirm the expression of HEPH by stromal elements infiltrating the tumor microenvironment and endothelial cells; in addition we clearly detected expression of the ferroxidase in cellular elements belonging to the innate-immunity, such as macrophages and neutrophils, as identified based on morphological features.

Discussion

246 Lung cancer still represent the leading cause of cancer-related deaths both in men and women,
247 especially in developed countries. Lung adenocarcinoma is the most common histologic subtype,
248 whose incidence has dramatically arose and overcome that of squamous cell carcinoma due to an
249 increase in the incidence of lung cancer in women. Despite advances in diagnosis and treatments, the
250 overall 5-year survival rate remains dismal especially when lung cancer is diagnosed at advanced
251 stages (27). Therefore, a better understanding of the molecular mechanisms underlying lung
252 carcinogenesis should contribute to the development of novel strategies for its preventions and
253 therapy. Cigarette smoking represents the principal risk factor for lung cancer, but inhalation of air
254 pollutants is also accountable for the increased incidence of this type of malignancies. Air pollution
255 and tobacco smoking have been shown to impact on lung iron metabolism, being the source of
256 additional iron supply on a tissue which is physiologically exposed to oxidative stress. In the present
257 studies we identified HEPH, a protein involved in exporting iron out from the cell, as promising
258 predictor for the clinical prognosis in lung cancer.

259 HEPH is a multi-copper oxidase whose function has been better characterized in small
260 intestine, where it is required for iron egress from the enterocyte into the circulatory system. HEPH
261 is thought to work in concert with Ferroportin (FPN1), the only known mammalian iron exporter for
262 non-heme iron, whose down-regulation has been monitored in several cancers and it is usually
263 correlated to a poor prognosis (12). FPN1 reduction is thought to act by increasing the concentration
264 of the intracellular labile iron pool, the catalytic/reactive iron, which, on one side, is required to
265 sustain the high metabolic demand of actively proliferating cells, but, on the other hand, it can trigger
266 the production of free radical species, further boosting the oxidative damage. In lung FPN1 is facing
267 the lumen of the alveoli and this localization has been attributed to a role in iron detoxification (10).
268 Indeed, environmental iron arriving to the lung epithelium can be initially buffered by the activity of
269 the antioxidant molecules such as ascorbic acid, reduced glutathione, and mucin, and once loaded on
270 transferrin and lactoferrin herein present, it can undergo transferrin receptor 1 (TfR1) and lactoferrin
271 receptor (LfR) internalization by epithelial alveolar cells and alveolar macrophages and be safely
272 stored bound to ferritin (28). Under iron overload condition the excess of pulmonary iron can be
273 release into the lumen of the alveoli via FPN1 permease and possibly oxidize by GPI-anchored or
274 soluble ceruloplasmin, an HEPH homologue ferroxidase (29). Based on our immunohistochemical
275 localization studies, HEPH has emerged to be highly expressed not in the lung epithelium, as
276 functional partner of apically located FPN1, but on the endothelial cells of the lung vasculature and
277 in some perivascular cells (pericyte/fibroblast cells). HEPH has been already identified on endothelial
278 cells of brain capillaries (30). In this context the ferroxidase has been shown to be localized on the
279 endothelium abluminal side, as well as on pericytes, where it is supposed to convert ferrous iron

280 released in the extracellular space by endothelial FPN1 into ferric iron, thus limiting oxidative
281 damage. A similar mechanism could also operate in lung, where endothelial localized HEPH could
282 similarly act on nutritional ferrous iron shipped in the interstitial space by FPN1, making it available
283 for resident cell uptake, thus limiting oxidative damage. This precise architectural organization and
284 functional interplay between endothelial cells, pericytes and alveolar epithelial cells is compromised
285 under pathological conditions such as cancer, and somehow reorganize to foster cancer cells
286 proliferation.

287 Based on our bioinformatics analysis, further corroborated by immunohistochemistry, cancer
288 cells in LUAD and LUSC are mostly not expressing (LUAD) or poorly expressing, with a variable
289 degree, HEPH. This reduction is expected to limit FPN1-dependent iron export, which needs the
290 concomitant ferroxidase activity to fully function as a Fe^{2+} permease. The consequent increase in the
291 intracellular labile iron pool, via ROS generation, can stimulate cell proliferation and survival by
292 inducing several pro-survival signalling pathways and promote epithelial-to-mesenchymal transition
293 (EMT), an essential step for the initiation of metastasis. Innate immune cells and cancer-associated
294 fibroblasts are also a major source of iron and ROS in the tumour microenvironment (31).

295 According to TIMER bioinformatics analysis, HEPH expression has emerged to be strongly
296 and positively correlated with cancer associated fibroblasts (CAFs). Upon LUAD and LUSC
297 specimens HEPH immunolabeling, we clearly identified HEPH expressing cells characterized by an
298 elongated spindle-shaped morphology typical of fibroblasts, enveloping some tumour nests in LUSC
299 cancer histotype. CAFs are the most dominant cellular component in the tumour stroma which not
300 only provide physical support to tumour cells but also play key role in promoting or hampering
301 tumorigenesis in a context-dependent manner. CAFs are highly heterogeneous cell population due to
302 their multiple origins: they can arise from resident fibroblasts, bone marrow-derived progenitor cells
303 or epithelial/endothelial cells that have undergone epithelial to mesenchymal transition. Cellular
304 trans-differentiation, both from stromal cell to stromal cell and from tumour cell to stromal cell have
305 all been described, being fibroblast trans-differentiation into activated myofibroblast, positive for α -
306 SMA expression, the most frequently cited example. With the aim to better characterize our HEPH
307 positive stromal elements we performed HEPH/ α -SMA double-labelling experiments but we observe
308 that a restricted minority of cells were for both antigens (data not shown). This observation raises the
309 possibility that these tumour-associated stromal elements could belong to the most aggressive “matrix
310 remodelling” subtypes, as classified by Marini and colleagues (21), which are characterized by
311 increased expression of fibroblast activating protein (FAP) but low expression of α -SMA. It is
312 interesting to note that FAP mRNA expression is the only marker emerged to be slightly upregulated,

even though not reaching a statistical significance, in LUAD and LUSC as compared to normal tissue (Figure 4A). Further in-depth studies will be required to unravel all these issues.

As far as innate immunity is concern, neutrophils and macrophages, as detected by MPO and CD14 immunoreactivity, were also identified as HEPH expressing cells infiltrating the tumour tissues under investigation. Neutrophils, the hallmark of acute inflammation, have been shown to represent a substantial proportion of the immune infiltrate in a wide variety of cancer types, including lung cancer, even though their role is still debated (32). Tumour-associated neutrophils (TANs) could exert a beneficial anti-tumour function, based on their high cytotoxic potential that could be directed toward cancer cells (33). On the other hand, other studies support the notion that TANs would, instead, promote tumour progression based on their ability to release angiogenic factors, and other mediators able to stimulate cell motility, migration and invasion. Almost nothing is known regarding how alteration in iron handling by neutrophils would impact on their activity in a tumoral context. These cells utilize iron-dependent ROS production through a process called respiratory or oxidative burst and iron is required for both neutrophil NADPH oxidase and MPO activities as a component of the catalytic site (34, 35). Under iron overload conditions, it has been shown that ROS production by neutrophils is significantly impaired (36). Since LUAD and LUSC infiltrating neutrophils express HEPH, making them able to avoid intracellular iron overload, this may indicate that they are fully competent to execute their cytotoxic potential, thus exerting an anti-tumour activity. They could also participate in iron clearance upon release of lactoferrin contained in their secondary granules.

In most malignancies tumor associated macrophages (TAM) are characterized by an iron-release phenotype required to sustain tumor growth and mediate immune suppression in the tumor microenvironment (37). Recently it has been shown that TAMs exposed to hemolytic red blood cells, event occurring upon extravasation of erythrocytes from newly formed vessels, can be reprogrammed from M2-like into pro-inflammatory (M1-like) phenotype, thus able to kill tumour cells (38). Interestingly these observations were performed on lung adenocarcinoma affected patients, further underlying the complexity TAM phenotypes can acquire as a consequence of different cytokine/chemokine composition found on the tumour niche.

In conclusion, our study has further underlined the complex, and still poorly understood, association existing between iron metabolism and the cancerogenic mechanisms operating in different organ landscape. Bioinformatics analysis, based on mRNA expression dataset, indicate HEPH as a novel potential prognostic biomarker for lung cancer pathologies. Up-regulation of HEPH in LUAD and LUSC correlates with a better out-come, but only from the full comprehension of the functional cross-talk occurring between the different cell types identified as HEPH-expressing cells and cancer cells will allow us to envision new therapeutic strategy to fight such devastating diseases.

347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370

ETHICS STATEMENT

This study was carried out in accordance with the Declaration of Helsinki and was approved by the University of Palermo Ethical Review Board (approval number 09/2018).

CONFLICT OF INTEREST

The author declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

Conception and design: Paola Zacchi, Alessandro Mangogna and Violetta Borelli. Development of methodology: Paola Zacchi, Alessandro Mangogna. Acquisition of data: Beatrice Belmonte, Letizia Scola, Gaia Morello and Anna Martorana. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, and computational analysis): Alessandro Mangogna, Paola Zacchi and Violetta Borelli. Writing, review, and/or revision of the manuscript: Paola Zacchi, Alessandro Mangogna and Violetta Borelli. Study supervision: Violetta Borelli.

FUNDINGS

This work was supported by grants from the Italian League for the Fight Against Cancer (LILT), Gorizia section (Bando di Ricerca sanitaria 2017-programma 5 per mille anno 2015).

ACKNOWLEDGEMENTS

We thank prof. Giuliano Zabucchi for critical review of the manuscript and Dr. Armando Gentile for his technical assistance.

371 **Table 1.** Correlation analysis between HEPH expression and immune infiltration level of the
372 indicated immune cells. The “Purity Adjustment” option was applied to all analysis performed.

373

	LUAD		LUSC	
	<i>Rho</i>	<i>p</i>	<i>Rho</i>	<i>p</i>
Purity	-0.341	6.3e-15	-0.343	1.21e-14
CD8+ T cell	0.184	3.9e-05	0.273	1.38e-09
CD4+ T cell	0.167	2.03e-04	0.233	2.55e-07
Macrophages	0.406	5.7e-21	0.206	5.89e-06
Neutrophis	0.285	1.03e-10	0.278	6.15e-10

374

375

376 **Figures' legends**

377

378 **Figure 1.** Pathological significance of HEPH expression in different types of human cancers and in-
379 depth evaluation in LUAD and LUSC. (A) Human HEPH expression levels in different tumour types
380 from TCGA database were determined by TIMER (*P < 0.05, **P < 0.01, ***P < 0.001). (B) HEPH
381 mRNA expression comparisons between normal and tumour tissues were further obtained from the
382 GEPIA web tool. (C) HEPH protein expression comparison between normal and tumour tissues
383 obtained from the UALCAN web tool (Wilcoxon test). P-value < 0.05 was used to assess
384 differences.(D) Survival analyses of HEPH by Kaplan–Meier estimator with log-rank test obtained
385 from the Kaplan Meier plotter web tool. Survival differences are compared between patients with
386 high and low (grouped according to Auto select best cut-off) expression of HEPH. H, high expression;
387 L, low expression.

388

389 **Figure 2.** Correlation of HEPH expression with infiltration level of non-immune cells in LUAD and
390 LUSC. HEPH expression is significantly negatively related to tumour purity and has significant
391 positive correlations with infiltrating levels of cancer-associated fibroblasts and endothelial cells.

392

393 **Figure 3.** HEPH expression positively correlated with markers of cancer-associated fibroblasts and
394 endothelial cells in both LUAD and LUSC. Scatterplots of correlations between HEPH and gene
395 markers include ACTA2, FAP, PDGFRA, PDGFRB for cancer-associated fibroblasts and PECAM1
396 (CD31) and vWF for endothelial cells.

397

398 **Figure 4.** Overall survival curve of each cancer-associated fibroblasts and endothelial marker shown
399 to correlate to HEPH expression and produced by Kaplan-Meier website resource. OS differences are
400 compared between patients with high and low (grouped according to Auto select best cut-off). H,
401 high expression; L, low expression.

402

403 **Figure 5.** HEPH distribution in “normal” lung. Representative microphotographs relative to HEPH
404 expression by the endothelial cells (red arrows), cells of the myelomonocyte lineage cells including
405 monocytes, macrophages, and granulocytes (black arrows) in “healthy” pulmonary parenchyma.
406 Original Magnification 20X (A) and 40X (B).

407

408 **Figure 6.** HEPH distribution in lung adenocarcinoma specimen. Representative microphotographs
409 relative to HEPH expression in two different lung adenocarcinoma affected patients (A-C and higher

magnification B-D). The tumour tissue is infiltrated by some HEPH positive myelomonocyte lineage cells including monocytes, macrophages, and granulocytes (black arrows). Original Magnification 20X (A) and 40X (B).

Figure 7. HEPH distribution in lung squamous cell carcinoma specimen. Representative microphotographs relative to HEPH expression in two different lung squamous cell carcinoma affected patients (A-C and higher magnification B-D). The tumour tissue is infiltrated by some HEPH positive stromal elements (panel D, green arrows) and cells of the myelomonocyte lineage cells including monocytes, macrophages, and granulocytes (black arrows). Original Magnification 20X (A) and 40X (B).

REFERENCES

1. Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer Classifications *Ann Glob Health*. (2019) 85:1-16. doi: 10.5334/aogh.2419
2. Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO Classification. *Front Oncol*. (2017) 7:193. doi: 10.3389/fonc.2017.00193
3. Lorelei de Jesus A, Rahman M, Mazaheri M, Thompson H, Knibbs LD, Jeong C, et al. Ultrafine particles and PM_{2.5} in the air of cities around the world: Are they representative of each other? *Environment International* (2019) 129:118-135. doi.org/10.1016/j.envint.2019.05.021
4. Ying Chen, Zhimin Fan, Ye Yang, Chunyan Gu. Iron metabolism and its contribution to cancer. *International Journal of oncology* (2019) 54: 1143-1154
5. Cloonan SM, Mumby S, Adcock IM; Choi AMK, Chung KF, Quimlan GJ. The “Iron”-y of iron overload and iron deficiency in chronic obstructive pulmonary disease. *American Journal of respiratory and critical care medicine*. (2017) 196:1103-1112. doi: 10.1164/rccm.201702-0311PP
6. Ghio, A.J. Disruption of iron homeostasis and lung disease. *Biochim. Biophys. Acta* 2009, 1790:731–739. doi: 10.1016/j.bbagen.2008.11.004
7. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. (2010) *Cell* 142:24-38. doi: 10.1016/j.cell.2010.06.028.
8. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, Anderson GJ. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. *Nat Genet* (1999) 21:195-9. doi: 10.1038/5979.
9. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. *Molecular Cell* (2000) 5:299-309 doi: 10.1016/s1097-2765(00)80425-6

10. Yang F, Haile DJ, Wang X, Dailey LA, Stonehuerner JG, Ghio AJ. Apical location of ferroportin 1 in airway epithelia and its role in iron detoxification in the lung. *Am J Physiol Lung Cell Mol Physiol* (2005) 289: L14 – L23. doi.org/10.1152/ajplung.00456.2004
11. Drakesmith H, Nemeth E, Ganz T. Ironing out Ferroportin. *Cell Metabolism* (2015) 22:P777-787 doi.org/10.1016/j.cmet.2015.09.006
12. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr., Kute T, Willingham MC, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. *Sci Transl Med* (2010) 2:43ra56. doi: 10.1126/scisignal.3001127
13. Crovella S, Bianco AM, Vuch J, Zupin L, Moura RR, Trevisan E, Schneider M, et al. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study. *J Toxicol Environ Health A* (2016) 79:129-41. doi: 10.1080/15287394.2015.1123452.
14. Celsi F, Crovella S, Moura RR, Schneider M, Vita F, Finotto L, Zabucchi G, Zacchi P, Borelli V. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes. *J Toxicol Environ Health A* (2019) 82(20):1-15. doi.org/10.1080/15287394.2019.1694612
15. Wang Y, Zhang J, Su Y, Shen Y, Jiang D, Hou Y, Geng M, Ding J, Chen Y. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. *Front Genet.* (2020) 11: 579636. doi: 10.3389/fgene.2020.579636
16. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia* (2017) 19: 649–658. doi: 10.1016/j.neo.2017.05.002
17. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Research* (2017) 45: W98–W102. doi: 10.1093/nar/gkx247
18. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Research* (2020) 48:W509–W514. doi.org/10.1093/nar/gkaa407
19. Weinstein JN, Collisson EA, Mills GB, Shaw KM, Ozenberger BA, Shmulevich KEI, Sander C, Stuart JM, and Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer Analysis Project. *Nat Genet.* (2013) 45: 1113–1120. doi:10.1038/ng.2764.
20. An Y, Liu F, Chen Y, Yang Q. Crosstalk between cancer-associated fibroblasts and immune cells in cancer. *J Cell Mol Med* (2020) 24:13-24. Doi:10.1111/jcmm.14745
21. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. *Breast Cancer Research* (2016) 18:84 doi 10.1186/s13058-016-0740-2
22. Nagy A, Lánckzy A, Menyhárt O, Györffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. *Scientific Reports* (2018) 8:9227
23. Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and Cancer. *Annu Rev Nutr* (2018) 38:97- doi: 10.1146/annurev-nutr-082117-051732.
24. Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C. Combined Total Genome Loss of Heterozygosity Scan of Breast Cancer Stroma and Epithelium Reveals Multiplicity of Stromal Targets. *Cancer Research* (2004) 64:7231-6. doi: 10.1158/0008-5472.CAN-04-2866

25. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell MJ, Rønnov-Jessen L. Epithelial to Mesenchymal Transition in Human Breast Cancer Can Provide a Nonmalignant Stroma. *Am J Pathol.* (2003) 162: 391–402. doi: 10.1016/S0002-9440(10)63834-5.
26. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts. *Cancer Res.* (2007) 67:10123–10128. doi: 10.1158/0008-5472.CAN-07-3127
27. Saab S, Zalzal H, Rahal Z, Khalifeh Y, Sinjab A, Kadara H. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. *Front. Immunol.* (2020) 11:1-21. doi.org/10.3389/fimmu.2020.00159
28. Zhang V, Nemeth E, Kim A. Iron in lung pathology. *Pharmaceuticals* (2019) 12: 30. doi: 10.3390/ph12010030
29. Harris ZL, Durley AP, Man Tk, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. *Proc. Natl. Acad. Sci. USA* (1999) 96:10812-10817
30. Burkhart A, Skjorringe T, Johnsen KB, Siupka P, Thomsen LB, Nielsen MS, Thomsen LL, Moos T. Expression of iron-related proteins at the neurovascular unit supports reduction and reoxidation of iron from transport through the blood-brain barrier. *Mol Neurobiol* (2016) 53:7237-7253 doi 10.1007/s12035-015-9582-7
31. Weinberg F, Ramnath N, Nagrath D. Reactive Oxygen Species in the Tumor Microenvironment: An Overview. *Cancers* (2019) 11(8): 1191 doi: 10.3390/cancers11081191
32. Mukaida N; Sasaki S, Baba T. Two-Faced Roles of Tumor-Associated Neutrophils in Cancer Development and Progression. *Int. J. Mol. Sci.* (2020) 21:3457. doi:10.3390/ijms21103457
33. Fridlender ZG, Sun J, Kim S Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF- β : ‘N1’ versus ‘N2’ TAN,” *Cancer Cell* (2009) 16:183–194. doi: 10.1016/j.ccr.2009.06.017
34. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. *J Exp Med.* (2013) 210:1283-1299.
35. Lambeth JD. NOX enzymes and the biology of reactive oxygen. *Nat Rev Immunol.* (2004) 4:181-189
36. Renassia C, Louis S, Cuvellier S, Boussetta N, Deschemin JC, Borderie D, Bailly K, et al. Neutrophils from hereditary hemochromatosis patients are protected from iron excess and are primed. *Blood Advances* (2020) 4: 3853- 3863 doi.10.1182/bloodadvances.2020002198.
37. Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-Associated Macrophages: Recent Insights and Therapies. *Front Oncol.* (2020) 10:188. doi: 10.3389/fonc.2020.00188
38. Costa da Silva M, Breckwoldt MO, Vinchi F, Correia MP, Stojanovic A, Thielmann CM, Meister M, et al. Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. *Front Immunol.* (2017) 8:1479. doi: 10.3389/fimmu.2017.01479

Figure 1

A

B

C

D

Figure 2

Figure 3

A Cancer associated fibroblasts markers

B Endothelial cells markers

Figure 4

Figure 5

Figure 6

LUAD

Figure 7

LUSC